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A B S T R A C T
Objectives: Biological predisposition for specific metastatic organs might differ between molecular subgroups of
lung cancer. We aimed to assess the association between molecular status and metastatic organs at diagnosis in a
nationwide stage IV non-squamous non-small cell lung cancer ((ns)-NSCLC) cohort.
Methods: All ns-NSCLC from 2013 that were stage IV at diagnosis were identified from the Netherlands Cancer
Registry, which records information on metastatic organs at diagnosis. Tumors were matched to the Dutch
Pathology Registry (PALGA) from which data on molecular status established in routine practice was extracted.
Four molecular subgroups (EGFR+, KRAS+, ALK+, triple-negative) were identified. For each metastatic organ,
proportions of tumors metastasized to this organ were, per molecular subgroup, compared to triple-negative
tumors by multivariable logistic regression analyses (adjusted odds ratios (OR) with 95% confidence intervals
(CI)), taking clinicopathological variables into account.
Results: 160 EGFR+ (exon 19 del, exon 21 L858R), 784 KRAS+, 42 ALK+, and 1008 triple-negative tumors
were identified. Most frequent metastatic organs were the bone (34%), pleura (24%), lung (23%), and brain
(22%). Compared to triple-negatives, EGFR+ tumors had more often metastases to the bone (31.5 vs 53.8%; OR
2.55 (95% CI 1.80–3.62)) and pleura (24.1 vs 37.5%; OR 2.06 (1.42–2.98)), and less often to the brain (22.0 vs
12.5%; OR 0.53 (0.32–0.88)) and adrenal glands (19.1 vs 7.5%; OR 0.46 (0.28–0.75)). Compared to triple-
negatives, KRAS+ and ALK+ tumors had at diagnosis metastasized more often to the lung (20.3 vs 26.7%; OR
1.40 (1.12–1.76)) and the liver (13.1 vs 23.8%; OR 2.07 (1.00–4.32)), respectively.
Conclusion: NSCLC molecular status was associated with metastatic pattern at diagnosis. 54% of stage IV EGFR+
ns-NSCLC patients had bone metastases at diagnosis. These observational results are hypothesis generating, and
call for a prospective study where EGFR+ patients are screened for bone metastases, and treated to prevent
skeletal related events.
1. Introduction
Non-squamous non-small cell lung cancer ((ns)-NSCLC) is often
driven by molecular alterations, such as Kirsten rat sarcoma mutations
(KRAS+), epidermal growth factor receptor mutations (EGFR+), and
anaplastic lymphoma kinase rearrangements (ALK+) in 25–30%,
10–15% and 5% of Caucasian ns-NSCLC patients, respectively [1,2].
EGFR+ is a favorable prognostic factor and predictive for response to
EGFR tyrosine kinase inhibitors (TKI) [3]; ALK+ is predictive for re-
sponse to ALK-TKI [4]. Currently no effective KRAS-targeted therapy is
available.
The biological predisposition for specific metastatic organs might
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differ between molecular subgroups. Understanding these differences
might have implications for adequate metastasis screening and (pro-
phylactic) treatment decisions. The biological predisposition is best
studied in treatment naïve stage IV patients to exclude bias from
treatment. Patients with EGFR+ NSCLC, for example, have a longer
overall survival (OS) compared to patients with EGFR-wildtype (wt)
disease, resulting in a longer time span for metastases to develop.
Several studies have suggested that the cumulative incidence of brain as
well as bone metastases may be higher in patients with EGFR+ NSCLC
as compared to EGFR-wt [5–7]. Studies (N=189-1063) evaluating
bone and brain metastases at initial stage IV diagnosis have reported
conflicting results [8–11].
Due to the relatively low number of included patients and the single
or dual-centre setting, the studies published thus far were unable to
adequately address the question whether biological predisposition for
metastatic organs differs between molecular subgroups [5,7–11]. Some
studies investigated the cumulative incidence of metastases to specific
organs, but not the burden of metastases at diagnosis [5–7]. Further-
more, most studies focused on one or two metastatic organs and/or
molecular alterations (mostly EGFR+) [5,8,9,11].
To evaluate the association of molecular status with organs of me-
tastases at diagnosis, we conducted a retrospective population-based
study in the Netherlands by linking data of stage IV ns-NSCLC from the
Netherlands Cancer Registry (NCR) to pathology data (including mo-
lecular analysis data established in routine practice) retrieved from the
Dutch Pathology Registry (PALGA).
2. Patients and methods
2.1. Patient selection
In the Netherlands, all patients diagnosed with cancer are registered
in the NCR, managed by the Netherlands Comprehensive Cancer
Organisation (IKNL). Data in the NCR is actively collected from patient
records according to standardized formats by trained data managers
[12], and include, but is not limited to: gender, age at diagnosis,
morphology code (ICD-O 3rd edition), TNM-stage (7th edition, 2013),
diagnosis of previous malignancy, and organs of metastases at diag-
nosis. Organs of metastases are recorded according to documented
clinical data (cTNM) with a maximum of three separate locations. In
cases with ≥3 organs, two are recorded and the third is coded as ≥3.
Organ count is irrespective of the number of metastases within this
organ. Furthermore, the NCR has a non-mandatory variable for in-
dicating whether 18FDG-PET was used for staging. The Dutch NSCLC
guideline [13] states that staging should involve a contrast-enhanced
computed tomography (CT) of the chest and the upper abdomen in-
cluding the adrenals. 18FDG-PET is recommended for all patients eli-
gible for therapy with curative intent. In daily practice, 18FDG-PET and
CT of the chest and upper abdomen are often combined in one session.
Specific data per hospital were not available.
All stage IV adenocarcinomas and NSCLC not otherwise specified
(NOS) diagnosed between January 1 2013 and December 31 2013 re-
corded in the NCR were selected. To exclude possible bias due to pre-
vious treatment, only patients with stage IV lung cancer at initial di-
agnosis were included. Patients with a recent history of cancer (i.e.
malignancy within five years before NSCLC diagnosis, except for skin
tumors other than melanoma and non-invasive tumors) were excluded.
Data were matched to PALGA by means of a trusted third party
(ZorgTTP, Houten, the Netherlands). PALGA has nationwide coverage
since 1991 and contains excerpts of all Dutch pathology reports of
histological and cytological examinations [14]. The data request was
approved by the scientific and privacy committees of IKNL and PALGA.
2.2. Data extraction and handling
Data on molecular tumor status established in routine practice in
pathology laboratories across the Netherlands was extracted manually
from relevant pathology reports. These are observational data of in-
cident cases and therefore include both primary and metastatic tumor
lesions evaluated by cytology, biopsy or resection specimens, which-
ever was available. Extracted data included molecular testing for EGFR,
KRAS and ALK, date of obtaining the tissue for molecular testing, and
mutation/rearrangement status. In routine pathology practice, different
techniques were used, including high resolution melting (HRM),
(Sanger) sequencing, quantitative PCR, and next-generation sequencing
(NGS) to test for EGFR and KRAS mutations, and fluorescence in situ
hybridization (FISH) and immunohistochemistry (IHC) to test for ALK
rearrangement. Tumors with molecular alterations identified on pa-
thology material obtained ≥3 months after diagnosis, with multiple
molecular alterations, or with alterations in other driver genes were
excluded.
Four molecular subgroups were defined: EGFR+, KRAS+, ALK+,
and triple-negative. Triple-negative was defined as negative for all three
genes, or EGFR/KRASwt without ALK testing, as only 50% of EGFR/
KRASwt tumors underwent ALK testing in 2013 (Kuijpers et al. sub-
mitted). Furthermore, as ALK+ is relatively uncommon (∼5%), the
number of actual ALK+ tumors in this subgroup was expected to be
minimal. EGFR mutations were categorized into classic activating mu-
tations (exon 19 deletions and exon 21 L858R point mutations), non-
classic activating mutations, resistance mutations, and other mutations
(i.e. for which in literature no information on EGFR-TKI sensitivity was
available).
2.3. Statistical analysis
Statistical analysis was performed with SPSS (version 20; SPSS Inc.,
Chicago, IL). Patient characteristics were described according to mo-
lecular status, and differences were assessed by t-test or Χ2-test when
applicable. For each organ of metastasis, proportions of tumors me-
tastasized to this organ were, per molecular subgroup (EGFR+, KRAS
+, and ALK+), compared to the triple-negative subgroup, and clin-
icopathological variables age (continuous), gender, histology (adeno-
carcinoma vs. NSCLC-NOS), and local disease status (≤T2 and≤N1 vs.
≥T3 and/or ≥N2, excluding cases with unknown T-stage) were taken
into account. Only the classic activating EGFR+ were included in the
analyses. Crude odds ratios (OR) with 95% confidence intervals (CI)
were calculated by univariable logistic regression analyses with triple-
negative as the reference category, and variables with a p-value< 0.2
were included in backward multivariable logistic regression analyses to
calculate adjusted ORs with 95% CIs. The same was done for the sub-
types of classic EGFR mutations and KRAS mutations with an incidence
of> 50.
OS was calculated from day of diagnosis till death. Median OS was
compared between molecular subgroups and in the EGFR+, KRAS+
and triple-negative subgroups between organs of metastases by stan-
dard Kaplan–Meier analysis, which does not control for confounders,
and tested for significance with Log-rank test. Patients who were alive
at December 31 2015 or who were lost-to-follow-up were censored at
last date of follow-up.
3. Results
3.1. Included patients
In 2013, a total of 8608 NSCLC were identified from the NCR, of
which 5462 (63.4%) were adenocarcinoma or NSCLC-NOS, and 3323
(60.8%) of those were stage IV (for 37/5462 tumors (0.7%), stage could
not be assessed). Eventually, 2052 tumors (2052 patients) were in-
cluded: 218 EGFR+, 784 KRAS+, 42 ALK+, and 1008 triple-negative
(486/1008 with unknown ALK status). Reasons and numbers of ex-
cluded tumors are summarized in Fig. 1. All included tumors were
pathologically confirmed (either the primary tumor, lymph node or
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distant metastasis), and 1784 tumors (89.5%) were histologically con-
firmed.
Of the EGFR+, 160 (73%) were classic activating mutations (90
exon 19 deletions and 70 exon 21 L858R point mutations), 19 (9%)
non-classic activating mutations, 31 (14%) resistance mutations, and 8
(3%) other mutations. Of the KRAS+, 587 (75%) had a mutation in
codon 12 (most commonly G12C (n=303), G12 V (n=129), G12A
(n=63), and G12D (n= 59)), 53 (7%) in codon 13, 27 (3%) in codon
61, 1 (0.1%) in codon 68, and for 116 patients (15%), the specific KRAS
mutation was not reported.Mean age of KRAS+ (P=0.037) and ALK+
patients (P=0.006) was significantly lower than of triple-negative
patients (Table 1). The EGFR+ and KRAS+ subgroups contained sig-
nificantly more female patients and adenocarcinomas than the triple-
negative subgroup (P < 0.0001). EGFR+ had significantly lower local
disease status than triple-negative (P=0.049).
In 701 cases (35.2%), the mutation/rearrangement was observed
(or tested for in case of triple-negative result) in a cytology specimen
only and in 1293 cases (64.8%) in a histology specimen (with or
without cytology). In 828 cases (41.5%) the mutation/rearrangement
was observed (or tested for in case of triple-negative result) in a primary
tumor specimen (either alone or in combination with testing in a
(lymph node) metastasis), and in 1166 cases (58.5%) in a (lymph node)
metastasis specimen only.
3.2. Association of molecular status and metastatic organs
The most common organs of metastases were the bone (N=1320;
33.8%), pleura (N=469; 23.5%), lung (N=460; 23.1%), brain
(N=438; 22.0%), adrenal glands (N= 363; 18.2%), liver (N=273;
13.7%), and extrathoracic lymph nodes (N= 226; 11.3%).
Compared to triple-negative patients, EGFR+ patients had sig-
nificantly more often bone metastases (53.8% vs. 31.5%); OR 2.55
(95% CI 1.80–3.62), pleural metastases (37.5% vs. 24.1%; OR 2.06
(1.42–2.98)), and less often brain metastases (12.5% vs. 22.0%; OR
0.53 (0.32–0.88)) and adrenal gland metastases (7.5% vs. 19.1%; OR
0.37 (0.20–0.68)) (Fig. 2). KRAS+ patients had significantly more often
lung metastases (26.7% vs. 20.3%; OR 1.40 (1.12–1.76)) than triple-
negative, and ALK+ patients showed a trend towards more often liver
metastases (23.8% vs. 12.9%; OR 2.07 (1.00–4.32)) than triple-negative
patients.
The most common combinations of organs with metastases were
bone+ adrenal glands (N= 129; 6.5%), bone+ liver (N=115; 7.8%),
bone+ lung (N=115; 7.8%), bone+ pleura (N=93; 4.7%), and
brain+ adrenal glands (N=65; 3.3%). Compared to triple-negative
patients, EGFR+ patients had significantly more often a combination of
bone with liver (11.3% vs. 4.7%); OR 2.59 (95% CI 1.46–4.59), lung
(10.6% vs 4.8%); OR 2.21 (95% CI 1.23–3.96), and pleural metastases
(9.4% vs. 4.5%); OR 2.46 (95% CI 1.32–4.57). ALK+ patients also had
significantly more often a combination of bone and liver metastases
than triple-negative patients (11.9% vs. 4.7%; OR 2.76 (1.04–7.35)),
3.3. Association of molecular driver subtypes and metastatic organs
Compared to triple-negative patients, those with an EGFR exon 19
deletion and L858R mutation more often had bone metastases (exon 19
deletion: 47.8%; OR 2.05 (1.31–3.20); L858R: 61.4%; OR 3.40
(2.04–5.66)) and pleural metastases (exon 19 deletion: 36.7%; OR 2.02
(1.26–3.26); L858R: 38.6%; OR 2.10 (1.25–3.54)) (Fig. 3). Further-
more, patients with an EGFR exon 19 deletion less often had adrenal
gland metastases (5.6% vs. 19.1%; OR 0.27 (0.11–0.67)) and patients
with an L858R mutation less often had brain metastases (10.0% vs.
22.0%; OR 0.44 (0.20–0.98)).
Patients with a KRAS G12A mutation more often had metastatic
disease to the bone than triple-negative patients (42.9% vs. 31.5%; OR
2.26 (1.33–3.81)) and with a G12 V mutation more often to the lung
(29.5% vs. 20.3%; OR 1.60 (1.05–2.45)) (Fig. 4).
3.4. Overall survival in relation to molecular status and metastatic organs
Median follow-up of censored cases was 30.2 months. Median OS
Fig. 1. Flowchart of tumor inclusion.
*No molecular testing or only of one or two genes with negative or indefinite
results, except for those tested and negative for EGFR and KRAS.
# 8 tumors with EGFR+ and KRAS+, 1 with EGFR+ and ALK+, and 2 with
KRAS+ and ALK+.
¥ 14 BRAF mutations, 4 PIK3CA mutations, 4 NRAS mutations, 4 ROS-1 re-
arrangements, 4 HER-2 mutations/translocations, and 2 c-MET amplifications
Table 1













Male 36.9%*** 44.9%*** 57.1% 61.4%
Female 63.1% 55.1% 42.9% 38.6%
Histology
Adenocarcinoma 98.1%*** 92.0%*** 95.2% 85.5%
NSCLC-NOS 1.9% 8.0% 4.8% 14.5%
N-stage
N0-1 28.7% 24.1% 21.4% 23.8%
N2-3 71.3% 75.9% 78.6% 76.2%
Local disease status¥
≤T2 and ≤N1 16.9%* 11.0% 7.1% 11.3%
≥T3 or ≥N2 80.6% 86.2% 90.5% 85.4%
T unknown 2.5% 2.8% 2.4% 3.3%
Number of organs with metastases
1 46.9% 50.8% 45.2% 54.3%
2 33.1% 27.6% 40.5% 27.8%
≥3 20.0% 21.7% 14.3% 18.0%
PET imaging performed
Yes 9.4% 8.8% 4.8% 9.2%
Unknown 90.6% 91.2% 95.2% 90.8%
# Classic activating EGFR mutations.
¥ Unknown T-stage excluded from comparison.
* P-value compared to triple negative< 0.05.
** < 0.01.
*** < 0.001.
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was significantly higher for EGFR+ (18.2 months) and ALK+ (15.4
months), but not for patients with KRAS+ NSCLC (8.8 months), as
compared to triple negative disease (8.9 months) (p < 0.001). In all
molecular subgroups, liver metastasis was associated with worse OS
compared to absence of liver metastases (Table 2). Only in KRAS+
NSCLC, bone, pleural, and adrenal gland metastases were associated
with worse OS as well.
4. Discussion
In this nationwide population-based study of treatment-naive stage
IV ns-NSCLC we evaluated the association of molecular status and
metastatic organs. Classic activating EGFR+ was associated with a
higher frequency of bone and pleural metastases and a lower frequency
of brain and adrenal gland metastases as compared to triple negative
tumors. KRAS+ had a higher frequency of lung metastases, whereas
ALK+ showed a higher frequency of liver metastases than triple-ne-
gative tumors.
The lower frequency of brain metastases in EGFR+ patients is in
contrast to previous studies [5,7–9]. In the Dutch guideline on NSCLC,
brain imaging is only advised in symptomatic patients [13]. Data on
neurological symptoms or brain imaging were not available to us.
Hence, some preclinical brain metastases might be missed, but we as-
sume the distribution of patients without brain imaging to be similar
between the molecular subgroups.
We confirmed the higher frequency of bone metastases in EGFR+
patients reported by others [6,8]. As 54% of the EGFR+ stage IV ns-
NSCLC patients had bone metastases at diagnosis, a prospective trial
screening all EGFR+ patients for bone metastases is worth considering.
This advice would also fit in the current ESMO clinical practice
guideline [15], which states that only selected NSCLC patients, with
symptomatic or asymptomatic bone metastases, with a life ex-
pectancy>3months, and considered at high risk of skeletal related
events (SREs), should be treated with zoledronic acid or denosumab to
prevent SREs. However, it is not defined in this guideline which specific
type of NSCLC patient fits this description, and our results may help in
defining potential candidates. Results regarding the risk of SREs in
EGFR+ patients are conflicting and it is currently not clear whether
EGFR-TKI can prevent all SREs [11,16]. In vitro, EGFR signaling plays
an important role in osteoclastogenesis and RANKL activation, and
RANKL transactivates EGFR [17]. Adding a bone targeted agent to
EGFR-TKI therapy might decrease the risk of SREs in EGFR+ patients.
Bisphosphonates were shown to enhance the EGFR-TKI antitumor effect
[18]. The RANKL inhibitor Denosumab might also act synergistically
with EGFR-TKI, but, to our knowledge, no (preclinical) data exist.
Also in line with previous studies are the lower incidence of adrenal
gland metastases [6] and the higher incidence of pleural metastases in
EGFR+ patients vs. triple-negative patients [19,20], and the higher
incidence of lung and liver metastases in KRAS+ [21] and ALK+
[6,10] patients, respectively, vs. triple-negative patients. KRAS+ G12A
tumors had more often metastases in the bone than triple-negative tu-
mors. In literature, the risk of bone being the first site of recurrence or
metastasis was higher in G12C mutated surgically resected tumors than
in wt, EGFR+, and other KRAS+ tumors, but only 2 tumors with a
G12A mutation were described [7].
Strengths of this study are the inclusion of only treatment-naive
Fig. 2. Comparison between molecular subgroups in the pro-
portions of tumors metastasized to the seven most common
metastatic organs.
*P-value compared to triple negative< 0.05, **< 0.01,
***< 0.001 adjusted for clinicopathological variables (bone:
gender, histology and local disease status; pleura: gender, age,
histology and local disease status; lung: age, histology and
local disease status; brain: gender, age, histology and local
disease status; adrenal gland: age, histology and local disease
status; liver: none; lymph node: age and local disease status).
Fig. 3. Comparison between subtypes of EGFR classic acti-
vating mutations in the proportions of tumors metastasized to
the seven most common metastatic organs.
*P-value compared to triple negative< 0.05, **< 0.01,
***<0.001 adjusted for clinicopathological variables (bone:
gender, histology and local disease status; pleura: gender, age,
histology and local disease status; lung: age, histology and
local disease status; brain: gender, age, histology and local
disease status; adrenal gland: age, histology and local disease
status; liver: none; lymph node: age and local disease status).
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stage IV ns-NSCLC patients, excluding bias from previous treatments,
and its population-based character using uniformly registered data from
nationwide registries, excluding selection bias (which might be the case
in single-centerstudies) and enabling inclusion of large numbers of
patients.
This study has a few limitations. First, the number of ALK+ patients
was still relatively low, possibly because in the Netherlands in 2013
only 24% of stage IV ns-NSCLC were tested for ALK rearrangement,
representing 50% of the EGFR/KRASwt tumors (Kuijpers et al., sub-
mitted). Patient numbers per specific molecular driver subtype (e.g.
KRAS G12A, EGFR exon 19 deletion) were small and no definitive
conclusions can be drawn for these specific subtypes. Second, EGFR/
KRASwt tumors without ALK testing were included as triple-negative,
but similar results were obtained when these tumors were excluded
from analyses. Third, only classic EGFR+were included, but analysis of
all EGFR+ produced similar results (data not shown). Bias due to the
type and site of available specimens is not expected. The proportions of
tumor samples with a tumor cell percentage of ≤10%, ≤20% and
≤30%, and the proportion of tumors where the mutation/rearrange-
ment was observed in cytology only (or tested for in case of triple-ne-
gative) did not differ significantly between tumors with and without a
driver mutation (i.e. EGFR+/KRAS+/ALK+ vs. triple-negative). In
addition, although triple-negative tumors had significantly more often
molecular testing performed on (lymph node) metastasis specimens
only than tumors with a driver mutation/rearrangement (61.5% vs
55.4%; P=0.005), triple-negative patients were deemed truly triple-
negative, as mutations are in principle truncal, and therefore expected
to be present in the primary tumor and in the metastases. Fourth, only
up to three organs with metastatic sites are coded in the NCR. When
there are metastases in ≥3 organs, two are recorded and the third is
coded as ≥3, This might result in bias regarding reporting of organs
with specific metastases. However, as all data managers are trained to
score in the same format,we presume that this did not result in
reporting bias between the different molecular groups. Finally, data on
18FDG-PET scan performance, which can detect more metastases than
CT alone, was only available for a limited number of patients (evenly
distributed between the molecular subgroups). Reporting of staging
procedures such as 18FDG-PET, bone scan or magnetic resonance ima-
ging (MRI) is an optional instead of a mandatory item in the NCR. It is
therefore probable that a number of 18FDG-PET staged patients were
not scored as such in our analysis. Reporting of metastatic organs de-
pended on available imaging information. The lack of detailed staging
information is a limitation of our study, however, staging procedures
are not dependent on molecular status and according to the Dutch
NSCLC guideline all patients should receive at least a CT of the chest
and upper abdomen, and therefore we assume that this will not have
caused bias with regard to reporting organs of metastases. Moreover,
the NCR does not include data on WHO performance status (PS) of the
patients while this is of prognostic significance. However, in the pro-
posals for the M-descriptors of the 8th TNM classification [22], 18FDG-
PET and WHO PS data were also not available, but still M1a/M1b
showed better outcomes than M1c, suggesting that results without
18FDG-PET staging data and WHO PS data can be used for these kind of
analyses.
5. Conclusion
In conclusion, molecular status of NSCLC is associated with organs
of metastasis at diagnosis. 54% of stage IV EGFR+ ns-NSCLC patients
had bone metastases at diagnosis. These observational results are hy-
pothesis generating, and call for a prospective study in which EGFR+
patients are screened for bone metastases, and treated to prevent SREs.
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